** Shares of medical device maker ResMed RMD.N fall 3.8% to $244.56
** RMD's rival Apnimed said late on Monday that its oral pill met the main goal in a late-stage study to treat obstructive sleep apnea
** Apnimed's experimental drug, AD109, showed a mean reduction of 55.1% on a scale that measures mild, moderate and severe obstructive sleep apnea
** Apnimed says the drug significantly improved oxygenation and reduced disease severity in patients
** It plans to submit a marketing application to the U.S. FDA for the drug, AD109, by early 2026
** ResMed makes continuous positive airway pressure machines (CPAP), which offer a non-invasive treatment option for sleep apnea characterized by brief interruptions of breathing during sleep
** Including session's moves, RMD up 10.8% YTD
(Reporting by Siddhi Mahatole)
((siddhi.mahatole@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。